Pharmacotherapy of Duchenne Muscular Dystrophy
dc.contributor.advisor | Pórszász, Róbert | |
dc.contributor.advisordept | Department of Pharmacology and Pharmacotherapy | hu_HU |
dc.contributor.author | Umar, Muhammad Azeem Jalil | |
dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
dc.contributor.opponent | Szentmiklósi, József András | |
dc.contributor.opponent | Drimba, László | |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.contributor.opponentdept | Kenézy Kórház Központi Aneszteziológiai és Intenzív Terápiás Osztály | hu_HU |
dc.date.accessioned | 2018-09-26T08:30:42Z | |
dc.date.available | 2018-09-26T08:30:42Z | |
dc.date.created | 2017-04-21 | |
dc.description.abstract | Duchenne muscular dystrophy is a myopathic disease caused by mutations in the dystrophin gene. It is inherited in an X-linked recessive manner from mothers to their sons. The presentation is of progressive muscle weakness in the proximal limb muscles and then the distal muscles of the lower extremities. Eventually the muscle weakness affects the upper extremities. The symptoms begin at around 4 years of age. | hu_HU |
dc.description.corrector | hbk | |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | angol | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 30 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/257231 | |
dc.language.iso | en | hu_HU |
dc.subject | Duchenne Muscular Dystrophy | hu_HU |
dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
dc.title | Pharmacotherapy of Duchenne Muscular Dystrophy | hu_HU |